Meilin Zhu currently serves as a Program Manager at ODDITY LABS, starting in June 2024. Previously, Meilin Zhu was a Doctoral Student at the Broad Institute of MIT and Harvard from October 2019 to April 2024, where significant research focused on novel metabolic targets in the vaginal microbiome for bacterial vaginosis treatment, earning recognition from Bill Gates at a Gates Foundation summit. Additional experience includes a Business Development Internship at Concerto Biosciences, where competitive landscape analyses were conducted, and a Co-Director of Entrepreneurship role at the MIT Biotech Group, facilitating biotech education events. Early career experiences include undergraduate research positions at the ASU Biodesign Institute and the Chang Lab, as well as an NSF REU in sensor technology and an internship with PATH focused on malaria diagnostics. Meilin Zhu holds a PhD in Biological Engineering from MIT and a BS in Biochemistry from Arizona State University.
This person is not in the org chart
Ragon Institute of Mass General, MIT, and Harvard
1 followers
The Ragon Institute was established in 2009 with a dual mission: to contribute to the accelerated discovery of an HIV/AIDS vaccine and subsequently establish itself as a world leader in the collaborative study of immunology. Founded with a commitment of $100 million from Phillip T. (Terry) and Susan M. Ragon, and with an additional $200 million gift to endow the Institute announced on April 26, 2019, the Institute is structured and positioned to significantly contribute to a global effort to successfully develop an HIV/AIDS vaccine by: • Creating non-traditional partnerships among experts with different but complementary backgrounds; • Providing a means for rapidly funding promising studies; • Integrating key facets of vaccine development efforts that have tended to follow separate tracks; • Providing a substantial pool of accessible, flexible funding that lowers the threshold for scientists to pursue risky, unconventional avenues of study that are unlikely to attract funding from traditional sources. Such funding encourages innovation, compresses the time it takes to conduct bench-to-bedside research and attracts new minds to the field. The Ragon Institute creates a singular opportunity and environment to engage scientists, engineers and clinicians in challenging research for which there is no greater benefit – saving lives and curing the ill.